Nimesulide is a non-steroidal anti-inflammatory drug (NSAID) known for its selective inhibition of the cyclooxygenase-2 (COX-2) enzyme, which underlies its anti-inflammatory, analgesic, and antipyretic properties.
This article provides a comprehensive overview of nimesulide, covering its chemical nature, pharmacology, therapeutic applications, safety profile, and regulatory considerations.
Introduction
Nimesulide is an NSAID primarily used to treat acute pain, inflammation, and fever. It is notable for its relatively selective inhibition of the COX-2 enzyme, which differentiates it from traditional NSAIDs that inhibit both COX-1 and COX-2, potentially reducing gastrointestinal side effects.
It is chemically classified as a sulfonanilide and has been marketed under various brand names such as Mesulid and Aulin.
Chemical Structure
The chemical formula of nimesulide is C13H12N2O5S, with a molecular weight of approximately 308.31 g/mol. Structurally, it is characterized by two aryl groups: a phenyl and a 2-methylsulfonamido-5-nitrophenyl group. Its IUPAC name is N-(4-nitro-2-phenoxyphenyl)methanesulfonamide.
The molecule contains functional groups such as a nitro group, sulfonamide, and aromatic ether, contributing to its pharmacological activity.
Nimesulide-Based Medicines List
Some of the notable marketed formulations containing nimesulide include:
- Mesulid
- Aulin
- Flogovital
- Nimepast
- Nimesulida (generic formulations)
- Nimesulide tablets combined with paracetamol (common in some markets)
- Topical gels and creams containing nimesulide
- Combination products with other analgesics or decongestants (market-specific)
Mechanism of Action
Nimesulide exerts its therapeutic effects primarily through selective inhibition of the cyclooxygenase-2 (COX-2) enzyme, which is responsible for the synthesis of prostaglandins involved in inflammation and pain signaling. By blocking COX-2, nimesulide reduces the production of pro-inflammatory prostaglandins, leading to decreased inflammation, pain, and fever.
Its relative sparing of COX-1 is thought to contribute to a lower incidence of gastrointestinal adverse effects compared to non-selective NSAIDs.
Pharmacokinetics
Nimesulide is absorbed well orally, reaching peak plasma concentrations within 2 to 3 hours after administration. It undergoes hepatic metabolism primarily via cytochrome P450 enzymes, with metabolites excreted mainly in urine and feces.
The elimination half-life ranges from 1.8 to 4.7 hours, supporting twice-daily dosing in clinical use. Its pharmacokinetic profile facilitates rapid onset of analgesic and anti-inflammatory effects.
Therapeutic Uses
| Indication | Description |
|---|---|
| Acute pain | Relief of moderate to severe pain, including musculoskeletal pain |
| Osteoarthritis | Management of inflammation and pain in osteoarthritis |
| Primary dysmenorrhea | Alleviation of menstrual pain |
| Postoperative pain | Used to reduce pain and inflammation after surgery |
| Fever | Antipyretic use in febrile conditions |
Nimesulide is generally indicated for short-term use due to safety concerns, especially related to hepatic effects.
Side Effects
Common side effects of nimesulide include gastrointestinal disturbances such as nausea, vomiting, abdominal pain, and diarrhea. Skin reactions like rash and itching can occur. More serious but rare adverse effects include hepatotoxicity, which has led to restrictions in some countries.
Other potential side effects include dizziness, headache, and allergic reactions. Due to its risk profile, liver function monitoring is recommended during prolonged therapy.
Drug Interactions
Nimesulide may interact with other drugs metabolized by the liver, such as anticoagulants (e.g., warfarin), other NSAIDs, corticosteroids, and certain antihypertensives. Concomitant use with other hepatotoxic drugs should be avoided to reduce the risk of liver injury. It may also affect drugs that influence renal function or electrolyte balance.
Safety Considerations
Due to reports of hepatotoxicity, nimesulide is recommended for short-term use only, generally not exceeding 15 days. It is contraindicated in patients with active liver disease or impaired hepatic function. Use during pregnancy and lactation is generally discouraged. Caution is advised in patients with renal impairment or cardiovascular risk factors. Monitoring of liver enzymes is advised during treatment.
Regulatory Status
Nimesulide’s regulatory status varies globally. It is approved and widely used in some countries for short-term management of pain and inflammation but has been withdrawn or restricted in others due to safety concerns, particularly regarding liver toxicity. Regulatory agencies recommend careful patient selection and adherence to prescribed duration of therapy to mitigate risks.
In summary, nimesulide is a COX-2 selective NSAID with effective analgesic and anti-inflammatory properties. While it offers advantages in terms of gastrointestinal tolerability, its use is limited by concerns over hepatotoxicity, necessitating cautious prescribing and monitoring. Its chemical and pharmacological profile supports its role in managing acute pain and inflammation under appropriate clinical supervision.
